Dr. Muzumdar graduated from Harvard College and received his Doctorate of Medicine from the Stanford University School of Medicine. He completed his internship and residency in Internal Medicine at Brigham and Women's Hospital and a fellowship in Medical Oncology at the Dana-Farber Cancer Institute and Massachusetts General Hospital. He completed a postdoctoral research fellowship at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology before joining the Yale faculty.
His laboratory is interested in understanding the mechanisms by which genetic, environmental, and host factors contribute to cancer initiation, progression, and maintenance. Leveraging a combination of sophisticated genetically-engineered cell and animal models, the lab seeks to define the molecular basis for tumor cell and host adaptations that drive tumorigenesis. Furthermore, the lab uses genetic and pharmacologic approaches combined with novel nanoparticle-based delivery methods to augment or impede these adaptations and determine the consequences on cancer development in these models. The ultimate goal of this research is to identify novel approaches for cancer prevention and treatment.
|Damon Runyon-Rachleff Innovation Award||Damon Runyon Cancer Research Foundation||2021|
|New Innovator Award (DP2)||National Institutes of Health Director's Common Fund||2019|
|AACR NextGen Grant for Transformative Cancer Research||American Association for Cancer Research||2019|
|Early Career Award||American Association for Cancer Research (journal Cancer Research)||2019|
|Mentored Clinical Scientist Research Career Development Award (K08)||National Cancer Institute (NCI)||2016|
|Young Investigator Award||Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO)||2013|
|Allen B. Barbour Award for Excellence in Internal Medicine||Stanford University School of Medicine||2008|
|Research Training Fellowship for Medical Students||Howard Hughes Medical Institute||2005|
|Cancer Research||Reviewer||2022 - Present|
|Cellular and Molecular Life Sciences||Associate Editor||2022 - Present|
|Yale Pancreatic Cancer Collaborative (YalePaCC)||Director||2020 - Present|